-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
On November 6, Fudan Zhangjiang issued an announcement stating that its Class 1 new drug FZJ-003 capsule is an oral JAK1 selective inhibitor (specification: 25mg, 50mg) for the treatment of moderate to severe atopic dermatitis Phase II clinical trial application Accepted by the Food and Drug Administration
Atopic dermatitis (AD) is a chronic inflammatory disease, usually in the form of a skin rash
At present, biological agents dominate the field of treatment of moderate to severe AD.